|
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer. |
|
|
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD; Novartis; Pfizer; Roche; Takeda |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche |
|
|
Honoraria - AB Science; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Eisai; Janssen; Lilly O.; Merck Sharp & Dohme; Mirati Therapeutics; MSD; Novartis; Pfizer; Regeneron; Roche; Tessa Therapeutics |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Dr. Reddy's; Ipsen; MSD; Regeneron |
Other Relationship - Janssen; Lilly O.; Novartis; Pfizer; Taiho Pharmaceutical |
|
|
Honoraria - AstraZeneca; Novartis; Roche |
Other Relationship - Roche |
|
|
No Relationships to Disclose |
|
Christoph Matthias Ahlers |
Employment - Arcus Biosciences |
Stock and Other Ownership Interests - Arcus Biosciences |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Arcus Biosciences |
|
|
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Daiichi Sankyo/Lilly; Elevation Oncology; Kaleido Biosciences; Merck; Mirati Therapeutics; NGM Biopharmaceuticals; Pfizer; Roche/Genentech; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Elevation Oncology; Kaleido Biosciences; Merck; Merck KGaA; Mirati Therapeutics; NGM Biopharmaceuticals; Pfizer; Roche/Genentech; Takeda |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb |